RxDoctor Payments Data

Sunil Swami, MD

Internal Medicine · Aldie, VANPI 1942441373

Payments from drug & device makers

$4,720in general payments, 2019–2025

Across 218 payments — averaging $21.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$2K
  • AstraZeneca$1K
  • Regeneron Healthcare Solutions, Inc.$312
  • Boehringer Ingelheim$270
  • Mylan Specialty L.p.$231
  • Grifols USA, LLC$154
  • plus $971 from 22 others

What the payments were for

  • Consulting fees$150%
  • Food & beverage$4,67799%
  • Education$281%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,720 in reported general payments places this provider in the 90th percentile of 2,724 internal medicine providers in Virginia.

See all internal medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$53,948
Medicare patients
255
Services billed
593

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter272$186,923
NucalaMepolizumab21$92,735
Pirfenidone12$21,100
Breztri AerosphereBudesonide/Glycopyr/Formoterol26$21,013
Arnuity ElliptaFluticasone Furoate75$17,324
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr33$16,866
Stiolto RespimatTiotropium Br/Olodaterol Hcl17$9,942
Breo ElliptaFluticasone/Vilanterol16$8,715
Albuterol Sulfate HfaAlbuterol Sulfate239$6,264
Advair HfaFluticasone Propion/Salmeterol12$5,480
SymbicortBudesonide/Formoterol Fumarate22$5,047
Incruse ElliptaUmeclidinium Bromide14$4,952
Wixela InhubFluticasone Propion/Salmeterol28$2,942
Fluticasone-SalmeterolFluticasone Propion/Salmeterol20$2,373
Ventolin HfaAlbuterol Sulfate26$1,467

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Nucala, Arnuity Ellipta, Anoro Ellipta, Breo Ellipta$1,701$327,515431 claims
AstraZenecaBreztri Aerosphere, Symbicort$1,081$26,06048 claims
Boehringer IngelheimStiolto Respimat$270$9,94217 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,724 internal medicine providers in Virginia.

Other internal medicine in Aldie

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →